Last reviewed · How we verify

Sertralin — Competitive Intelligence Brief

Sertralin (Sertralin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Sertralin (Sertralin) — Poznan University of Medical Sciences.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sertralin TARGET Sertralin Poznan University of Medical Sciences marketed Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A
Zoloft sertraline Pfizer Inc. marketed SSRI (Selective serotonin reuptake inhibitor) Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A 1991-12-30

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sertralin — Competitive Intelligence Brief. https://druglandscape.com/ci/sertralin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: